The pharmacokinetic profile of Actrapid InnoLet has been studied in a small number (n=18) of diabetic children (aged 6-12 years) and adolescents (aged 13-17 years).
Iphrofayili ye-pharmacokinetic ye-Actrapid ® NM yafundwa ngenombolo encane (n = 18) yezingane (iminyaka engu-6-12 ubudala) kanye nentsha (iminyaka engu-13 kuya kwengu-13 ubudala) enesifo sikashukela.